IV Cisplatin

Phase 2Small molecule

UUniversitair Ziekenhuis Brussel

IV Cisplatin is one of 4 small molecule programs targeting Intratumoral Injection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intratumoral InjectionRecruiting

Intratumoral InjectionPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Intratumoral Injection

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

1 2

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

1 3

OH2

BBinhui Biopharmaceutical Co., Ltd.

Phase 1

1 4

IV Cisplatin

UUniversitair Ziekenhuis Brussel

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intratumoral Injection1 trial

Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab

Recruiting·UUniversitair Ziekenhuis Brussel·Phase 1/2·NCT03707808·18 enrolled

Lymphoma1 trial

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Withdrawn·NNational Cancer Centre, Singapore·Phase 1·NCT04230330

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IV Cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV Cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV Cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitair Ziekenhuis Brussel company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversitair Ziekenhuis Brussel

IV Cisplatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intratumoral Injection1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News